DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma

Despite intensive therapy, children with high-risk neuroblastoma are at risk of treatment failure. We applied a multiomic system approach to evaluate metabolic vulnerabilities in human neuroblastoma. We combined metabolomics, CRISPR screening, and transcriptomic data across more than 700 solid tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, Thale Kristin, Dyberg, Cecilia, Embaie, Bethel Tesfai, Alchahin, Adele, Milosevic, Jelena, Ding, Jane, Otte, Jörg, Tümmler, Conny, Hed Myrberg, Ida, Westerhout, Ellen M., Koster, Jan, Versteeg, Rogier, Ding, Han-Fei, Kogner, Per, Johnsen, John Inge, Sykes, David B., Baryawno, Ninib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798925/
https://www.ncbi.nlm.nih.gov/pubmed/35943801
http://dx.doi.org/10.1172/jci.insight.153836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798925/
https://www.ncbi.nlm.nih.gov/pubmed/35943801
http://dx.doi.org/10.1172/jci.insight.153836

Ejemplares similares